All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
The FDA grants UCART123 Investigational New Drug approval for treatment of AML
This month, the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) status to UCART123 for the treatment of patients with Acute Myeloid Leukemia (AML).1
UCART123 is an allogenic gene-edited Chimeric Antigen Receptor (CAR) T-cell therapy targeting CD123.1 CD123, the Interleukin 3 α-Chain Receptor (IL3RA), is differentially and significantly overexpressed in the majority of patients with AML. Additionally, CD123 has been identified as a marker for Leukemic Stem Cells (LSCs),2 which are a small population of stem cells that have properties including differentiation, self-renewal, and homeostatic control, and they contribute to the maintenance and propagation of AML. In AML, the LSC reservoir can lead to disease resistance, relapse, and often death in patients.3
Currently, UCART123 is at the preclinical stage of development.4 The IND approval granted by the FDA allows UCART123 to be evaluated in phase I clinical trials in AML patients. Trials are anticipated to start in the first half of this year.1
References